Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer

NCT01963182 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

First Line Metastatic Colorectal Cancer

Interventions

DRUG: Irinotecan

Sponsor

Centre Jean Perrin